Monday, 16 Sep 2019

You are here

Statins Don't Increase Risk of Colchicine Myopathy

Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.  

Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.

A Korean study compared 486 gout patients on colchicine against 188 on colchicine and a statin.

The incidence of myopathy was not significantly higher in those on both drugs than in those on colchicine alone (2.7% vs 1.4%, p = 0.330).

Risk factors for myopathy included chronic kidney disease (HR 29.1; 95% CI 4.38–192.4), liver cirrhosis (HR 10.7), higher colchicine doses (HR 21) and concomitant CYP 3A4 inhibitor use (HR 12.0). 

Concomitant use of statins did not increase the use of myopathy (HR 1.1; 95% CI 0.262–4.814) in gout patients on colchicine.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.